The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...
"By cleverly combining new techniques for analyzing DNA at the level of individual molecules, we can achieve real breakthroughs in research into conditions such as dementia," predicts Professor John ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results